Endocrine and Neuroendocrine Cancers

Edited by
January 2023
198 pages
  • ISBN978-3-0365-5763-2 (Hardback)
  • ISBN978-3-0365-5764-9 (PDF)

This book is a reprint of the Special Issue Endocrine and Neuroendocrine Cancers that was published in

Biology & Life Sciences
Medicine & Pharmacology

Endocrine and neuroendocrine tumors originate from endocrine cells but are heterogeneous in terms of clinical presentation, disease outcome, and treatments available.

This Special Issue addresses specific aspects of pre-clinical, clinical, and translational research and clinical management of these diseases with the aim of providing novel insights, addressing current unmet needs, and discussing future treatment perspectives.

  • Hardback
License and Copyright
© 2022 by the authors; CC BY-NC-ND license
neuroendocrine neoplasm; neuroendocrine carcinoma; Ki67 labeling index; Ki67 proliferation index; adrenocortical tissues; EMT; epithelial markers; mesenchymal markers; recurrence-free survival; neuroendocrine neoplasms; molecular targeted therapies; mTOR inhibitors; somatostatin analogs; TPH inhibitors; meta-analysis; medullary thyroid cancer; calcitonin; MEN2; gene carriers; adrenocortical cancer; metastatic pheochromocytoma; metastatic paraganglioma; checkpoint inhibitors; avelumab; ipilimumab; nivolumab; pembrolizumab; neuroendocrine tumor; GEP-NET; PET/CT; PRRT; DOTATOC; crcinoid crisis; neuroendocrine tumors; hemodynamic instability; octreotide; neuroendocrine; molecular profiling; targeted therapies; mutation; fusion; ctDNA; anaplastic thyroid carcinoma; chemotherapy; immune checkpoint inhibitors; tumors associated macrophages; radiotherapy; molecular targeted therapy; gastroenteropancreatic neuroendocrine neoplasms; patient-derived xenograft; tumor spheroids; somatostatin receptor-2; near infrared-labelled octreotide analog; neuroendocrine neoplasms; management; Delphi; consensus; pancreatic neuroendocrine tumor; everolimus; angiogenesis; circulating cells; biomarkers; n/a